pantoprazole

• October 2024: CRITICAL SHORTAGE of Canadian product.  Very limited supply of foreign product available.
• Conservation strategies must be followed to preserve supply :
  • Initiate PPI therapy with oral lansoprazole in all patients when clinically feasible 
  • Use intravenous histamine-2-receptor antagonists (H2RAs) such as famotidine, in place of intravenous pantoprazole when clinically appropriate

  • IV pantoprazole should be reserved to patients with active bleeding who cannot have oral medications (critical care areas exempt)

  • Patients on IV pantoprazole should be reassessed daily for transition to oral therapy (lansoprazole)

---

Go to Pediatric Parenteral Administration Information for pantoprazole

---

Acid Suppression (if unable to take oral)
5 to less than 20 kg

2 mg/kg/dose IV daily
Maximum: 40 mg/dose

Greater than or equal to 20 kg

1-1.5 mg/kg/dose IV daily
Maximum: 40 mg/dose

Upper GI Bleed
IV Continuous Infusion
5 to 40 kg

2 mg/kg/dose IV once followed by 0.2 mg/kg/hour IV infusion, for up to a maximum of 72 hours

Greater than 40 kg

80 mg IV once followed by 8 mg/hour IV infusion, for up to a maximum of 72 hours
Maximum: 8 mg/hour

---

Go to Neonatal Drug Dosing Guideline for pantoprazole

---

Supplied

Injection: 40 mg

---

For more detailed information, go to Micromedex

---

Created on July 31, 2019 10:58 AM
Updated on October 09, 2024 01:35 PM